Table 4.

Results of the univariate statistical analysis, given for three different patient groupings: (i) entire cohort, (ii) biopsy $\text{GG}>1$ subgroup patients, (iii) the entire cohort where clinically significant upgraded cases (from GG1 to $\text{GG}>1$) considered only.

	All patients		Biopsy $\text{GG}>1$ patients		Clinically significant GG upgrade cases
Total population	$\text{N}=95$		$\text{N}=75$		$\text{N}=95$
Upgraded cases	$\text{N}=27$		$\text{N}=10$		$\text{N}=17$
Clinical features	OR (CI)	P val.	OR (CI)	P val.	OR (CI)	P val.
Age	0.75 (0.50–1.14)	0.181	1.04 (0.66–1.64)	0.855	0.69 (0.45–1.05)	0.085
PSA	0.75 (0.48–1.17)	0.210	0.90 (0.57–1.42)	0.653	0.80 (0.52–1.23)	0.306
Prostate volume	0.97 (0.65–1.45)	0.866	0.95 (0.61–1.50)	0.841	1.00 (0.67–1.49)	0.994
PSAD	0.92 (0.61–1.38)	0.677	0.99 (0.63–1.56)	0.974	0.91 (0.60–1.36)	0.633
${\text{ADC}}_{\text{mean}}$	0.98 (0.66–1.46)	0.920	0.80 (0.51–1.28)	0.354	1.22 (0.81–1.83)	0.344
${\text{ADC}}_{\text{min}}$	1.03 (0.69–1.54)	0.879	0.79 (0.50–1.26)	0.322	1.29 (0.86–1.95)	0.220
Tumor size	1.50 (0.95–2.37)	0.079	1.95 (1.07–3.54)*	0.028*	0.93 (0.62–1.40)	0.734
Total biopsy core length	0.84 (0.56–1.26)	0.407	0.80 (0.51–1.27)	0.351	0.98 (0.65–1.46)	0.907
Total biopsy tumor length	0.76 (0.50–1.15)	0.191	1.00 (0.63–1.57)	0.989	0.71 (0.46–1.09)	0.116
TL/CL	0.82 (0.54–1.23)	0.332	1.11 (0.71–1.75)	0.651	0.72 (0.47–1.09)	0.115
PI–RADS	1.39 (0.92–2.10)	0.112	1.44 (0.91–2.29)	0.121	1.05 (0.70–1.57)	0.813
Tumor zone	1.00 (0.67–1.49)	0.990	1.05 (0.67–1.66)	0.820	0.94 (0.63–1.41)	0.774
Number of biopsy cores	0.48 (0.30–0.76)*	0.002*	0.59 (0.36–0.97)*	0.038*	0.71 (0.47–1.08)	0.111
Number of positive biopsy cores	0.56 (0.35–0.87)*	0.011*	0.69 (0.42–1.11)	0.121	0.71 (0.47–1.09)	0.115
Positive biopsy core ratio	0.96 (0.64–1.44)	0.858	1.03 (0.66–1.63)	0.881	0.91 (0.61–1.37)	0.649
Biopsy GG 1	0.14 (0.06–0.32)*	<0.001*

Statistically significant results are marked by an asterisks.

Significant values are in bold.